Ruxolitinib discontinuation syndrome: incidence, risk factors and management in 251 patients with myelofibrosis Contributor Blood Cancer Behind the paper Ruxolitinib discontinuation syndrome: incidence, risk factors and management in 251 patients with myelofibrosis Francesca Palandri Jan 15, 2021
